Liraglutide Patent Expiration
Liraglutide is Used for improving glycemic control and reducing the risk of cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. It was first introduced by Novo Nordisk Inc
Liraglutide Patents
Given below is the list of patents protecting Liraglutide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Saxenda |
US9968659 (Pediatric) | Liraglutide in cardiovascular conditions | Jul 09, 2037 | Novo |
| Victoza |
US9968659 (Pediatric) | Liraglutide in cardiovascular conditions | Jul 09, 2037 | Novo Nordisk Inc |
| Saxenda | US9968659 | Liraglutide in cardiovascular conditions | Jan 09, 2037 | Novo |
| Victoza | US9968659 | Liraglutide in cardiovascular conditions | Jan 09, 2037 | Novo Nordisk Inc |
| Victoza |
US9265893 (Pediatric) | Injection button | Mar 23, 2033 | Novo Nordisk Inc |
| Victoza | US9265893 | Injection button | Sep 23, 2032 | Novo Nordisk Inc |
| Saxenda |
US9132239 (Pediatric) | Dial-down mechanism for wind-up pen | Aug 01, 2032 | Novo |
| Saxenda | US9132239 | Dial-down mechanism for wind-up pen | Feb 01, 2032 | Novo |
| Saxenda |
US9457154 (Pediatric) | Injection device with an end of dose feedback mechanism | Mar 27, 2028 | Novo |
| Saxenda | US9457154 | Injection device with an end of dose feedback mechanism | Sep 27, 2027 | Novo |
| Saxenda |
US9687611 (Pediatric) | Injection device with torsion spring and rotatable display | Aug 27, 2027 | Novo |
| Saxenda | US9687611 | Injection device with torsion spring and rotatable display | Feb 27, 2027 | Novo |
| Saxenda |
USRE46363 (Pediatric) | Dial-down mechanism for wind-up pen | Feb 03, 2027 | Novo |
| Saxenda |
US10220155 (Pediatric) | Syringe device with a dose limiting mechanism and an additional safety mechanism | Jan 17, 2027 | Novo |
| Saxenda |
US8920383 (Pediatric) | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left | Jan 17, 2027 | Novo |
| Saxenda |
US9775953 (Pediatric) | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left | Jan 17, 2027 | Novo |
| Saxenda | US7686786 | Dial-down mechanism for wind-up pen |
Aug 03, 2026
(Expired) | Novo |
| Saxenda | USRE46363 | Dial-down mechanism for wind-up pen |
Aug 03, 2026
(Expired) | Novo |
| Saxenda |
US9108002 (Pediatric) | Automatic injection device with a top release mechanism |
Jul 26, 2026
(Expired) | Novo |
| Saxenda |
US9616180 (Pediatric) | Automatic injection device with a top release mechanism |
Jul 20, 2026
(Expired) | Novo |
| Saxenda |
US9861757 (Pediatric) | Injection device with an end of dose feedback mechanism |
Jul 20, 2026
(Expired) | Novo |
| Saxenda | US10220155 | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul 17, 2026
(Expired) | Novo |
| Saxenda | US11097063 | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul 17, 2026
(Expired) | Novo |
| Saxenda | US8920383 | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul 17, 2026
(Expired) | Novo |
| Saxenda | US9775953 | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul 17, 2026
(Expired) | Novo |
| Saxenda |
US8684969 (Pediatric) | Injection device with torsion spring and rotatable display |
Apr 20, 2026
(Expired) | Novo |
| Saxenda |
US8114833 (Pediatric) | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Feb 13, 2026
(Expired) | Novo |
| Victoza |
US8114833 (Pediatric) | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Feb 13, 2026
(Expired) | Novo Nordisk Inc |
| Saxenda | US9108002 | Automatic injection device with a top release mechanism |
Jan 26, 2026
(Expired) | Novo |
| Saxenda | US10357616 | Injection device with an end of dose feedback mechanism |
Jan 20, 2026
(Expired) | Novo |
| Saxenda | US10376652 | Automatic injection device with a top release mechanism |
Jan 20, 2026
(Expired) | Novo |
| Saxenda | US11311679 | Automatic injection device with a top release mechanism |
Jan 20, 2026
(Expired) | Novo |
| Saxenda | US9616180 | Automatic injection device with a top release mechanism |
Jan 20, 2026
(Expired) | Novo |
| Saxenda | US9861757 | Injection device with an end of dose feedback mechanism |
Jan 20, 2026
(Expired) | Novo |
| Saxenda | US11446443 | Injection device with torsion spring and rotatable display |
Oct 20, 2025
(Expired) | Novo |
| Saxenda | US8684969 | Injection device with torsion spring and rotatable display |
Oct 20, 2025
(Expired) | Novo |
| Saxenda | US8114833 | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Aug 13, 2025
(Expired) | Novo |
| Victoza | US8114833 | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Aug 13, 2025
(Expired) | Novo Nordisk Inc |
| Saxenda |
US7762994 (Pediatric) | Needle mounting system and a method for mounting a needle assembly |
Nov 23, 2024
(Expired) | Novo |
| Victoza |
US7762994 (Pediatric) | Needle mounting system and a method for mounting a needle assembly |
Nov 23, 2024
(Expired) | Novo Nordisk Inc |
| Saxenda | US7762994 | Needle mounting system and a method for mounting a needle assembly |
May 23, 2024
(Expired) | Novo |
| Victoza | US7762994 | Needle mounting system and a method for mounting a needle assembly |
May 23, 2024
(Expired) | Novo Nordisk Inc |
| Saxenda |
US8579869 (Pediatric) | Needle mounting system and a method for mounting a needle assembly |
Dec 30, 2023
(Expired) | Novo |
| Victoza |
US8579869 (Pediatric) | Needle mounting system and a method for mounting a needle assembly |
Dec 30, 2023
(Expired) | Novo Nordisk Inc |
| Saxenda | US8579869 | Needle mounting system and a method for mounting a needle assembly |
Jun 30, 2023
(Expired) | Novo |
| Victoza | US8579869 | Needle mounting system and a method for mounting a needle assembly |
Jun 30, 2023
(Expired) | Novo Nordisk Inc |
| Saxenda |
US6268343 (Pediatric) | Derivatives of GLP-1 analogs |
Feb 22, 2023
(Expired) | Novo |
| Victoza |
US6268343 (Pediatric) | Derivatives of GLP-1 analogs |
Feb 22, 2023
(Expired) | Novo Nordisk Inc |
| Saxenda |
US8846618 (Pediatric) | Stable formulation of modified GLP-1 |
Dec 27, 2022
(Expired) | Novo |
| Victoza |
US8846618 (Pediatric) | Stable formulation of modified GLP-1 |
Dec 27, 2022
(Expired) | Novo Nordisk Inc |
| Saxenda | US6268343 | Derivatives of GLP-1 analogs |
Aug 22, 2022
(Expired) | Novo |
| Saxenda |
US8672898 (Pediatric) | Automatic injection device with reset feature |
Jul 02, 2022
(Expired) | Novo |
| Saxenda |
US9486588 (Pediatric) | Automatic injection device with reset feature |
Jul 02, 2022
(Expired) | Novo |
| Saxenda |
US6899699 (Pediatric) | Automatic injection device with reset feature |
Jul 01, 2022
(Expired) | Novo |
| Saxenda | US8846618 | Stable formulation of modified GLP-1 |
Jun 27, 2022
(Expired) | Novo |
| Victoza | US8846618 | Stable formulation of modified GLP-1 |
Jun 27, 2022
(Expired) | Novo Nordisk Inc |
| Saxenda | US8672898 | Automatic injection device with reset feature |
Jan 02, 2022
(Expired) | Novo |
| Saxenda | US9486588 | Automatic injection device with reset feature |
Jan 02, 2022
(Expired) | Novo |
| Saxenda | US6899699 | Automatic injection device with reset feature |
Jan 01, 2022
(Expired) | Novo |
| Victoza |
USRE41956 (Pediatric) | Dose setting limiter |
Jul 21, 2021
(Expired) | Novo Nordisk Inc |
| Victoza | USRE41956 | Dose setting limiter |
Jan 21, 2021
(Expired) | Novo Nordisk Inc |
| Victoza | US6004297 | Injection syringe |
Jan 28, 2019
(Expired) | Novo Nordisk Inc |
| Victoza | USRE43834 | Injection syringe |
Jan 28, 2019
(Expired) | Novo Nordisk Inc |
| Saxenda | US6458924 | Derivatives of GLP-1 analogs |
Aug 22, 2017
(Expired) | Novo |
| Saxenda | US7235627 | Derivatives of GLP-1 analogs |
Aug 22, 2017
(Expired) | Novo |
| Victoza | US6268343 | Derivatives of GLP-1 analogs |
Aug 22, 2017
(Expired) | Novo Nordisk Inc |
| Victoza | US6458924 | Derivatives of GLP-1 analogs |
Aug 22, 2017
(Expired) | Novo Nordisk Inc |
| Victoza | US7235627 | Derivatives of GLP-1 analogs |
Aug 22, 2017
(Expired) | Novo Nordisk Inc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Liraglutide's patents.
Latest Legal Activities on Liraglutide's Patents
Given below is the list recent legal activities going on the following patents of Liraglutide.
| Activity | Date | Patent Number |
|---|---|---|
| ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 23 Oct, 2025 | US9968659 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 17 Feb, 2022 | US8846618 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 Oct, 2021 | US9968659 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 18 Oct, 2018 | US7235627 |
| Recordation of Patent Grant Mailed Critical
| 15 May, 2018 | US9968659 |
| Patent Issue Date Used in PTA Calculation Critical
| 15 May, 2018 | US9968659 |
| Email Notification Critical
| 26 Apr, 2018 | US9968659 |
| Issue Notification Mailed Critical
| 25 Apr, 2018 | US9968659 |
| Filing Receipt - Updated | 13 Apr, 2018 | US9968659 |
| Dispatch to FDC | 13 Apr, 2018 | US9968659 |
Liraglutide's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Liraglutide:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
| ||||
| Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | NA |
RECRUITING
(Aug 6, 2026)
| PHASE2 |
| SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity | Novo Nordisk A/S | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE3 |
| TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis | Talengen Institute of Life Sciences, Shenzhen, P.R. China. | NA |
RECRUITING
(Apr 1, 2026)
| PHASE1, PHASE2 |
| Phenserine on the Alzheimer's Treatment Horizon, Study 1 | Helse Stavanger HF | NA |
COMPLETED
(Apr 1, 2026)
| PHASE1 |